205 results about "Dry powder inhalation" patented technology

The invention relates to dry powder inhalation apparatus usually operable by breath of a user which provides for controlled and smooth transfer of medicament during multiple actuations by a user. A mechanism of the apparatus for achieving this controlled and smooth transfer includes a device (4) normally held adjacent a reservoir for receiving medicament in a cup or receptacle (15) and which is generally movable transversely of a longitudinal axis of the apparatus to delivery channels of the apparatus. This bodily shifting of the device (4) is achieved by a yoke acting on an abutment (16) thereof. Spillage of medicament in the apparatus is avoided.

The present invention relates to an improvement of the mouthpiece of a dry powder inhalation device wherein the medicament is packed in the blisters of single dose blister strips. According to the invention a portion of the air which enters the mouthpiece does not pass through the powder containing blister, but follows an alternative path through the mouthpiece, enabling therefore the modification of the resistance of the device in a simple and cost effective manner.

The invention relates to a dry powder inhalation with low-density or ultralow-density inhalable medicinal powder, a method for preparing the dry powder inhalation and application of the dry powder inhalation in preparing medicament for treating tumor, in particular lung tumor. The dry powder inhalation can deliver the tumor medicament to the lung directly so as to improve the medicament effect andreduce side effect; and the 'foaming' technology adopted for preparing the dry powder inhalation optimizes the micromeritic properties of the medicinal powder, and greatly improves the deposition performance of the tumor medicinal dry powder inhalation. The dry powder inhalation, the preparation method and the application thereof are also suitable for preparing non-vector dry powder inhalation toovercome the defects of uneven mixture between medicament and vector easily occurring in the dry powder inhalation.

The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion.

The invention provides a pyrazolopyrimidine compound shown as a structural formula (I), a pharmaceutical composition taking the pyrazolopyrimidine compound as an active component, a preparation method of the pyrazolopyrimidine compound and the pharmaceutical composition as well as an application of the pyrazolopyrimidine compound and the pharmaceutical composition in preparation of a TRPC6 (Transient Receptor Potential Channel 6) adjustor probe medicine and related medicines for preventing and treating glomerulopathy and myocardial hypertrophy. The pyrazolopyrimidine compound and derivatives provided by the invention can be used to prepare medical preparations in various forms which comprise oral liquids, injections, pulmonary inhalation preparations and transdermal preparations, specifically injections, oral liquids, troches, capsules, granules, aerosols, dry powder inhalation, patches and the like.

The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the present invention characterized by using a combination of: (1) a vessel housing a freeze-dried composition prepared by freeze-drying a composition liquid containing ingredients in a non-dissolved form, and has: (i) a non-powder cake-like form, (ii) a disintegration index of 0.05 or more, and (iii) a property of becoming fine particles having a mean particle diameter (mass median aerodynamic diameter) of 10 microns or less or a fine particle fraction of 10% or more upon receipt of an air impact having an air speed of at least 1 m/sec and an air flow rate of at least 17 ml/sec; and (2) a device comprising a member capable of applying said air impact to the freeze-dried composition in said vessel, and a member for discharging the powder-form freeze-dried composition that has been made into fine particles.

The invention belongs to the fields of polymer chemistry and medicinal preparations, and particularly relates to a method for synthesizing an active targeted hyaluronic acid-polylactic acid carrier, a method for preparing an anti-tumor medicinal micelle of the active targeted hyaluronic acid-polylactic acid carrier and an application thereof. By adopting a novel self-assembly technology, amphipathic PEG (polyethylene glycol) block polyester copolymer and tumor targeted ligand hyaluronic acid-polylactic acid copolymer are self-assembled by means of the electrostatic interaction to form a multifunctional composite micelle; the solubility of insoluble tumor medicaments and the drug loading capacity and encapsulation efficiency of water-soluble anti-tumor medicines can be remarkably improved by virtue of the anti-cancer drug-loaded micelle and composite micelle composition, the medicines can be biodegraded in a body, phagocytosis of a reticuloendothelial system (RES) and excretion of a kidney can be avoided. The active targeted hyaluronic acid-polylactic acid carrier has a long-circulating effect, the multifunctional composition has a prominent advantage of tumor active targeting effect, and parameters of pharmacodynamics in vitro and in vivo of the micelle are remarkably superior to those of common anti-tumor injections. Clinically acceptable administration means of the micelle includes injection administration or mucosal administration, and preparations of the micelle can be injection, transfusion, injection lyophilized powder injections or dry powder inhalation.

Taught herein is a disposable breath actuated dry powder drug inhalation device having a powderized drug storage chamber with integral toroidal geometry and air flow pathways for entraining and breaking up powder aggregates prior to delivery to the patient. The toroidal chamber is fluidly connected by one or more air inlets directed in a non-tangent manner toward the powder to loft and set up an irregular-rotational flow pattern. Also, in fluid connection with the toroidal chamber is a centrally or near centrally located air and powder outlet consisting of one or more holes forming a grid in fluid connection with a channel providing a passageway for powder flow to the patient.

The invention provides a pharmaceutical composition for a dry powder inhalation and a preparation method of the composition. The composition comprises a coating agent, lactose monohydrate for a carrier and micronized active pharmaceutical ingredients, wherein the coating agent is inhaled magnesium stearate or a combination of the inhaled magnesium stearate and micronized lactose monohydrate. The pharmaceutical composition for the dry powder inhalation and the preparation method of the composition have the advantages that the inhaled magnesium stearate with specific particle size characteristics or the combination of the inhaled magnesium stearate and the micronized lactose monohydrate serves as the coating agent to be applied to the composition for the dry powder inhalation, stimulus to the lung caused by deposition of magnesium stearate on the lung or other side effects can be avoided, in-vitro determining parameters of the active ingredients can be increased, fine particle proportion of the active ingredients can be increased, and the hydrothermal stability of the product can be improved.

The present invention relates to a dry powder inhalation device which is suitable for the simultaneous administration of a combination of pharmaceutical ingredients, wherein each pharmaceutical ingredient is packed in a separate blister of the same single dose blister strip. The medicaments that form the combination come into contact just before their exit from the mouthpiece of the device.

Described herein are interactive apparatus and methods for sensing and measuring real-time characteristic patterns of a subject's use of a dry powder inhalation system. The devices can be used in a wired or wireless communication mode to communicate with a display to assess the subject's usage of the inhalation system, to evaluate the performance of the inhalation system and/or to detect the characteristics profile of a dry powder formulation emitted from the inhalation system in use.

The invention relates to a dry powder inhaler with a constituent rubescensin A as well as a preparation method and application thereof. The dry powder inhaler is a medicinal composition formed by mixing the constituent rubescensin A as an active constituent with pharmaceutically acceptable excipients. Compared with orally administrated medicines, the dry powder inhaler developed by using the technical scheme provided by the invention greatly improves the effect of the constituent rubescensin A on treating esophagus cancers, lung tumors and leukemia.

The invention relates to the field of pharmaceutical preparations, and particularly relates to oseltamivir phosphate dry powder inhalations for treating influenza A and influenza B and a preparation method thereof. The oseltamivir phosphate dry powder inhalations are characterized in that the inhalations comprise oseltamivir phosphate and a co-atomizing agent in a weight ratio of (8:2)-(6:4). The oseltamivir phosphate dry powder inhalations provided by the invention have a simple preparation method, good fluidity, and good stability. After administration, the medicine can be metabolized to metabolites with anti-influenza virus activity, which can take an antibacterial effect and be used for preventing and treating influenza A and influenza B.

The dry powder inhalation composition comprising

• • (1) salmeterol xinafoate having mean particle size in range of 2.0μ-6μ microns and a tapped density in the range of 0.20 g·cm⁻³ to 0.45 g·cm⁻³ and
  • (2) optionally, one or more other active ingredients

and pharmaceutically acceptable carrier.

The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second particulate inhalant medicament. Also provided are dry powder compositions and methods of using them with a dry powder inhalation device.

A dry powder inhalation device is disclosed. In one optional aspect, the device includes a housing, a base plate, a receptacle for a medicament and a mouthpiece. The base plate is engageable with the housing to form a main space with a main air inlet. The mouthpiece includes an inner conduit connected to its outlet and is engageable with the base plate to fluidly connect the inner conduit to the receptacle. The receptacle is fluidly connected to the main space, so that upon inhalation by a user, air can be drawn through the main air inlet into the main space and onward through the receptacle into the inner conduit. The mouthpiece and the base plate form an auxiliary space with an auxiliary air inlet, wherein the auxiliary space is fluidly connected to the main space.

The invention relates to a dry powder inhalation dosing device and belongs to the field of inhalation type dosing instruments. A vibration gear is arranged below a dosing measuring module and provides longitudinal vibration for the dosing measuring module. Through a mode of single vibration or double vibration of medicine powder in a medicine powder storage container, the dry powder inhalation dosing device has good medicine powder adaptability and convenience in adjusting mechanical structure parameters design vibration effects, so that the metering accuracy of the medicine powder dose provided by a medicine storage unit in the process of medicine dosing by the whole dry powder inhalation dosing device each time is guaranteed better. The operating steps of the whole dry powder inhalation dosing device are simplified, and the better operating convenience is provided for the use by patients. When the dry powder inhalation dosing device is used, the complete medicine supply and dosing process can be achieved once only by manually rotating a rotating cover once respectively in the first rotating direction and the second rotating direction. The dry powder inhalation dosing device can be widely suitable for the fields of design and manufacture of dry powder inhalation dosing devices of various specifications.

The invention relates to a high-porosity dry powder inhaler carrier and its supersaturated synthesis method and application. The carrier is a flower-shaped porous dry powder particle with a rough surface, and the median diameter of a single particle under the electron microscope display is 0.5-50 microns. The loading capacity of drug molecules is 5-50% by mass, the N2 adsorption specific surface area of ​​the carrier is 10-100 square meters per gram, and contains micro, medium and macropores. The present invention combines supersaturated synthesis technology and flower-shaped material preparation technology for the first time, and applies it to the field of dry powder inhalers. The high-porosity dry powder inhaler carrier prepared by adopting the synthesis method provided by the present invention has controllable size and high The porosity nanopore system is applied to the adsorption, loading and transportation of nanoscale and molecular components, with good uniformity, stability and transmission efficiency. The invention realizes high-efficiency, high-quality, low-cost and practical mass production of nano- and micron-level high-porosity dry powder inhaler carrier materials.